Artiva Biotherapeutics, Inc. 8-K

What Happened

• Artiva Biotherapeutics, Inc. announced and filed an 8‑K (Item 2.02) on March 10, 2026 reporting its financial results for the year ended December 31, 2025.
• A press release with the results was attached to the filing as Exhibit 99.1. The 8‑K was signed by President and CEO Fred Aslan.

Key Details

• Filing date: March 10, 2026 (Form 8‑K, Item 2.02 — Results of Operations and Financial Condition).
• Reporting period: Year ended December 31, 2025.
• Exhibit: 99.1 — Press release dated March 10, 2026 (contains the detailed results).
• Signed by: Fred Aslan, M.D., President and Chief Executive Officer.

Why It Matters

• This filing alerts investors that Artiva has released its 2025 annual financial results (earnings/revenue and related commentary) and that the full details are available in the attached press release.
• Investors should review the press release and any subsequent filings (e.g., Form 10‑K or quarterly reports) for specific figures, trends in revenue or expenses, and management commentary to assess financial performance and implications for the stock.